ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q2 2026

Zinzino group reported Q2 revenue up 17% YoY. June sales in its key markets rose 14% to SEK 296.8 million, while total group revenue in June increased 15% to SEK 302.8 million (SEK 264.2 million). In Q2, group revenues rose 17% to SEK 914.9 million (from SEK 779.5 million), with Faun Pharma external sales reaching SEK 6.0 million.

Analysis

The setup is modestly constructive for ZNZNF, but the market should care more about the composition of growth than the headline rate. In direct-selling / wellness models, sustained top-line acceleration can re-rate the name only if it translates into higher active-rep productivity and repeat purchase rates; otherwise, revenue can be a lagging indicator of channel stocking. The immediate beneficiary is ZNZNF’s distribution network and any supplier base tied to its SKUs, while larger peer platforms like NUS and HLF face a small but real risk of distributor poaching if this growth is coming from market-share gain rather than a temporary promo cycle.

The second-order effect is margin leverage: if this growth is organic and repeat-driven, fixed SG&A and customer-acquisition costs should scale favorably over the next 1-3 quarters, which matters more for equity value than the revenue print itself. If, however, growth is being bought with incentives or front-loaded orders, gross margin and operating cash conversion will lag, and the stock can give back gains quickly once the market asks for earnings quality. PHMMF looks like a much smaller beneficiary; external sales momentum is directionally positive, but too small to drive a re-rating unless it signals broader customer demand or better factory utilization.

Contrarian view: the consensus may be underestimating the risk that double-digit growth is already embedded in expectations after a run of strong prints. For the next 1-3 months, the key falsifier is any slowdown in sequential growth or a margin miss on the upcoming quarter; over 6-18 months, the thesis breaks if revenue growth persists but operating income, cash flow, and active customer metrics do not inflect. I would treat this as a watch item rather than a high-conviction catalyst trade until margin and cohort data confirm the quality of demand.

Key Decisions for Investors

• Watchlist, not immediate trade: avoid chasing ZNZNF on the revenue print alone; wait for next-quarter gross margin, operating cash flow, and active customer/distributor data before assigning a valuation rerate.
• If you want exposure, consider a small tactical long ZNZNF only on a post-earnings pullback, with a 1-3 month stop if sequential growth or margin commentary rolls over.
• Relative-value idea only if follow-through confirms quality: long ZNZNF / short a weaker direct-selling peer such as NUS over the next 1-3 quarters, targeting multiple expansion on the outperformer if customer metrics hold.
• Set an alert on PHMMF for utilization and external sales cadence; it is likely a secondary beneficiary, but the setup is too small to justify a standalone position without evidence of sustained factory leverage.